Achieve an early onset of T-cell expansion and sustained viability with the novel CellGenix (Freiburg im Breisgau, Germany) T-cell medium (CellGenix® TCM).
Serum-free T-cell therapy manufacturing
CellGenix (Freiburg im Breisgau, Germany) T-cell medium (CellGenix® TCM) offers a serum-free and xeno-free alternative for rapid expansion of functional human T-cells. Due to stable glutamine in the formulation it is ready-to-use for T-cell cultures without the need for supplementation with human serum or glutamine. Many current T-cell therapy protocols rely on the addition of human serum.
Eliminating the use of human serum will reduce the failure rate in your manufacturing process due to the high lot-to-lot inconsistencies of serum. Since human serum is a limited resource and might not be available in large quantities it is unsuitable for commercial scale manufacturing. Furthermore, the human origin of serum poses a certain risk of containing adventitious agents and therefore does not meet global regulatory guidelines.
Early onset of T-cell expansion and sustained viability
T-cell culture in CellGenix TCM results in high cell numbers early after activation and throughout cell culture with high viability. This early onset of T-cell expansion allows for faster T-cell therapy manufacturing, which can significantly reduce your cost of goods.
Promotion of a central memory and early differentiated memory T-cell phenotype
During T-cell culture in CellGenix TCM a ‘young’ phenotype of naÃ¯ve T-cells/memory stem T-cells (TN/SCM cells) or central memory T-cells (TCM cells) is acquired. These phenotypes represent the most undifferentiated memory T-cell phenotypes, meaning that they have the highest proliferation potential, self-renewal properties and longer survival rates.
It has been shown that the engraftment and persistence of T-cell products in patients is associated with a TCM phenotype, rather than more differentiated memory phenotypes . TSCM are considered as even less differentiated cells with potentially even better persistence. It has been reported that for CD19 CAR-T cells the expansion of patient-infused cells is correlated with the frequency of CD8+ TSCM-like cells . It is therefore beneficial for your T-cell therapy product to obtain a central memory and early differentiated memory T-cell phenotype.
High proportion of cytokine producing cells including polyfunctional cells
An important aspect of T-cell functionality is the secretion of cytokines such as interleukin-2 (IL-2), interferon-gamma (IFN-Î³) and tumor necrosis factor-alpha (TNF-Î±). After cultivation in CellGenix TCM a high proportion of cytokine producing cells is obtained including polyfunctional cells (expressing more than one cytokine).
A recent report suggests that the combination of cell frequency and cytokine production levels of polyfunctional CD19 CAR-T cells is correlated with the clinical outcome in patients with non-Hodgkin lymphoma . Obtaining cytokine secreting T-cells, in particular polyfunctional cells, could therefore have a positive effect on the therapeutic response of your T-cell therapy product.
Interested to learn more about CellGenix TCM GMP-Prototype?
Read on: cellgenix.com/tcm
- Schmueck-Henneresse M, Omer B, Shum T et al. Comprehensive
approach for identifying the T cell subset origin of CD3 and CD28
antibody—activated chimeric antigen receptor—modified T cells. J Immunol. 199(1), 348—362 (2017).
- Xu Y, Zhang M, Ramos C et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are pre- served by IL-7 and IL-15. Blood. 123(24), 3750—3759 (2014).
- Rossi J, Paczkowski P, Shen Y et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 132(8), 804—814 (2018).
Have any additional questions about this story? Ask us in the comments, below.
Find out more in these top picks from the Editor:
- How to choose the best medium for CAR-T manufacturing
- CAR-T mesh shrinks ovarian tumors in mice
- Preparing your raw materials for commercial manufacture: an interview with Bernd Leistler